GUMDROP : NCI 07-C-0106 A randomized phase 2.5 study of 153Sm-EDTMP (Quadramet) with or without a PSA-TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer

Created by Marte, Jenn (NIH/NCI) [E], last modified by Channing Paller on Apr 14, 2012

Description:

Sm-153 is a radioactive isotope approved by the FDA for palliation. Preclinical data support the combined effects of vaccine and radiation therapy, and this study is evaluating the clinical benefit of vaccine and "targeted" radiation, with a primary outcome measure of 4-month progression-free survival.

Link:

http://www.clinicaltrials.gov/ct2/show/NCT00450619

Site:

NCI

Principal Investigator:

James L. Gulley